Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.
Diabetes Res Clin Pract
; 210: 111612, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38479447
ABSTRACT
Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fenofibrato
/
Doenças Cardiovasculares
/
Diabetes Mellitus Tipo 2
Limite:
Humans
Idioma:
En
Revista:
Diabetes Res Clin Pract
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Austrália
País de publicação:
Irlanda